Introduction to the EQIPD quality system
- PAASP, Germany
- Charité Universitätsmedizin, Germany
- Janssen Pharmaceutica NV, Belgium
- PAASP GmbH, Germany
- AAALAC International, Spain
- Porsolt, France
- Sanofi, France
- UCB, United Kingdom
- Novartis pharma, Switzerland
- Pfizer, United States
- University of Groningen, Netherlands
- Tel Aviv University, Israel
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany
- Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Germany
- Charles River Laboratories, France
- Cohen Veterans Bioscience, United States
- German Mouse Clinic, Germany
- Helmholtz Zentrum München, Germany
- Broad Institute of MIT & Harvard, United States
- PAASP, France
- Polish Academy of Sciences, Poland
- Institute of Pharmacology, Toxicology, and Pharmacy, Germany
- National Council of Science and Technology, Mexico
- The University of Lausanne, Switzerland
- University of Aberdeen, United Kingdom
- Radboud University Medical Center, Netherlands
- University of Belgrade, Serbia
- Institute of Science and Technology, Austria
- University of Helsinki, Finland
- Imperial College London, United Kingdom
- Avertim, Belgium
- University of Edinburgh, United Kingdom
Abstract
While high risk of failure is an inherent part of developing innovative therapies, it can be reduced by adherence to evidence-based rigorous research practices. Numerous analyses conducted to date have clearly identified measures that need to be taken to improve research rigor. Supported through the European Union's Innovative Medicines Initiative, the EQIPD consortium has developed a novel preclinical research quality system that can be applied in both public and private sectors and is free for anyone to use. The EQIPD Quality System was designed to be suited to boost innovation by ensuring the generation of robust and reliable preclinical data while being lean, effective and not becoming a burden that could negatively impact the freedom to explore scientific questions. EQIPD defines research quality as the extent to which research data are fit for their intended use. Fitness, in this context, is defined by the stakeholders, who are the scientists directly involved in the research, but also their funders, sponsors, publishers, research tool manufacturers and collaboration partners such as peers in a multi-site research project. The essence of the EQIPD Quality System is the set of 18 core requirements that can be addressed flexibly, according to user-specific needs and following a user-defined trajectory. The EQIPD Quality System proposes guidance on expectations for quality-related measures, defines criteria for adequate processes (i.e., performance standards) and provides examples of how such measures can be developed and implemented. However, it does not prescribe any pre-determined solutions. EQIPD has also developed tools (for optional use) to support users in implementing the system and assessment services for those research units that successfully implement the quality system and seek formal accreditation. Building upon the feedback from users and continuous improvement, a sustainable EQIPD Quality System will ultimately serve the entire community of scientists conducting non-regulated preclinical research, by helping them generate reliable data that are fit for their intended use.
Data availability
We have not generated any data
Article and author information
Author details
Sandrine Bongiovanni
Esmeralda Castaños-Vélez
Alexander Dityatev
Ernesto Prado Montes de Oca
Funding
Innovative Medicines Initiative (777364)
- Malcolm R MacLeod
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Mone Zaidi, Icahn School of Medicine at Mount Sinai, United States
Publication history
- Received: September 21, 2020
- Accepted: May 20, 2021
- Accepted Manuscript published: May 24, 2021 (version 1)
- Version of Record published: June 7, 2021 (version 2)
Copyright
© 2021, Bespalov et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,677
- Page views
-
- 383
- Downloads
-
- 19
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Introduction to the EQIPD quality system
eLife 10:e63294.
https://doi.org/10.7554/eLife.63294
Further reading
-
- Neuroscience
Individual sensory neurons can be tuned to many stimuli, each driving unique, stimulus-relevant behaviors, and the ability of multimodal nociceptor neurons to discriminate between potentially harmful and innocuous stimuli is broadly important for organismal survival. Moreover, disruptions in the capacity to differentiate between noxious and innocuous stimuli can result in neuropathic pain. Drosophila larval class III (CIII) neurons are peripheral noxious cold nociceptors and innocuous touch mechanosensors; high levels of activation drive cold-evoked contraction (CT) behavior, while low levels of activation result in a suite of touch-associated behaviors. However, it is unknown what molecular factors underlie CIII multimodality. Here, we show that the TMEM16/anoctamins subdued and white walker (wwk; CG15270) are required for cold-evoked CT, but not for touch-associated behavior, indicating a conserved role for anoctamins in nociception. We also evidence that CIII neurons make use of atypical depolarizing chloride currents to encode cold, and that overexpression of ncc69—a fly homologue of NKCC1—results in phenotypes consistent with neuropathic sensitization, including behavioral sensitization and neuronal hyperexcitability, making Drosophila CIII neurons a candidate system for future studies of the basic mechanisms underlying neuropathic pain.
-
- Neuroscience
UBE3A encodes ubiquitin protein ligase E3A, and in neurons its expression from the paternal allele is repressed by the UBE3A antisense transcript (UBE3A-ATS). This leaves neurons susceptible to loss-of-function of maternal UBE3A. Indeed, Angelman syndrome, a severe neurodevelopmental disorder, is caused by maternal UBE3A deficiency. A promising therapeutic approach to treating Angelman syndrome is to reactivate the intact paternal UBE3A by suppressing UBE3A-ATS. Prior studies show that many neurological phenotypes of maternal Ube3a knockout mice can only be rescued by reinstating Ube3a expression in early development, indicating a restricted therapeutic window for Angelman syndrome. Here, we report that reducing Ube3a-ATS by antisense oligonucleotides in juvenile or adult maternal Ube3a knockout mice rescues the abnormal electroencephalogram (EEG) rhythms and sleep disturbance, two prominent clinical features of Angelman syndrome. Importantly, the degree of phenotypic improvement correlates with the increase of Ube3a protein levels. These results indicate that the therapeutic window of genetic therapies for Angelman syndrome is broader than previously thought, and EEG power spectrum and sleep architecture should be used to evaluate the clinical efficacy of therapies.
